Marksans Pharma Ltd.

India Inc's Overseas Investment Dips 32% at $1.23 Billion in July

Statement Of Investor Complaints For The Quarter Ended June 2018

No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disp...

Financial Result Updates

Marksans Pharma Limited has submitted to the Exchange, the financial results for the period ended March 31, 2018.

Dividend

Marksans Pharma Limited has informed the Exchange that Board of Directors at its meeting held on May 30, 2018, recommended Final Dividend of 0.05 per ...

Press Release

Marksans Pharma Limited has informed the Exchange regarding a press release dated May 30, 2018, titled "Press Release".

Board Meeting-Closure of Trading Window

This is to inform you that the Meeting of the Board of Directors of the Company will be held on Wednesday, 30th May, 2018 at Mumbai, to consider and a...

Board Meeting - Board Meeting On Wednesday, 30Th May, 2018

This is to inform you that the Meeting of the Board of Directors of the Company will be held on Wednesday, 30th May, 2018 at Mumbai, to consider and a...

Shareholding for the Period Ended March 31, 2018

Marksans Pharma Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2018. For more details, kindly Click here

Regulation 40 (9) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015.

Regulation 40 (9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Dear Sir, With reference to above captioned subject, pl...

Compliance Certificate For The Period Ended 31.03.2018

Reg. 7(3) RTA Compliance Certificate for the period ended 31.03.2018

Statement Of Investor Complaints For The Quarter Ended March 2018

No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disp...

Announcement under Regulation 30 (LODR)-Change in Directorate

Appointment of Mr. Digant Mahesh Parikh as Independent Director

Appointment

Marksans Pharma Limited has informed the Exchange regarding Appointment of Mr Digant Mahesh Parikh as Independent Director of the company w.e.f. March...

Announcement under Regulation 30 (LODR)-Press Release / Media Release

Press Release dated 12.02.2018

Board Meeting-Outcome of Board Meeting

Sub: Unaudited Financial Results for the quarter ended 31st December, 2017 and Limited Review Reports thereon. Dear Sir, In terms of Regulation 33 of ...

Press Release

Marksans Pharma Limited has informed the Exchange regarding a press release dated February 12, 2018, titled "Press Release ".

Financial Result Updates

Marksans Pharma Limited has submitted to the Exchange, the financial results for the period ended December 31, 2017.

Outcome of Board Meeting

Marksans Pharma Limited has informed the Exchange regarding Outcome of Board Meeting held on February 12, 2018.

Updates

Marksans Pharma Limited has informed the Exchange regarding 'Dividend Distribution Policy of the Company approved and adopted by the Board of Director...

Shareholding for the Period Ended December 31, 2017

Marksans Pharma Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2017. For more details, kindly Click here

Statement Of Investor Complaints For The Quarter Ended December, 2017

Statement of Investor Complaints for the quarter ended December, 2017 under Regulation 13(3) of SEBI (LODR), 2015.